SignalFDA/Bio

PFIZER: STILL CHEAP VALUATION MEETS A LOOMING PATENT CLIFF - SEEKINGALPHA

Cheap valuation plus looming patent cliff signals high-risk, high-scrutiny biotech catalyst.

What changed

Cheap valuation plus looming patent cliff signals high-risk, high-scrutiny biotech catalyst.

Why it matters

Cheap valuation plus looming patent cliff signals high-risk, high-scrutiny biotech catalyst. — impact context not separately stored; see What changed.

Sources

seekingalpha